Replies to post #246103 on Avid Bioservices Inc (CDMO)

[BCS Paladin]

that human clinical trial data "talks" and pre-clinical data walks

I sure wish I had posted this...I missed my chance to look like a genius.

[asmarterwookie]

Great posts nuke...I am/was hoping all the current data is the cake an the Sunrise plus new trial data are the icing. : )

wook

[Couch]

But when it comes to icing the big deal I believe what I stated in my post; that management believes its going to take human trial validation up to at least response data in more than just a Bavi + chemo trial to get the big deal closed.

Its evident enough to me after being in this stock over 10 years now and looking at the Biotech world for the amount of time that I have, that human clinical trial data "talks" and pre-clinical data walks. Unless of course someone wants to sell on the cheap.

Nuke, Elvis C could not have said it better. Music to my ears - So where are the strong
And who are the trusted? And where is the harmony? Sweet harmony.

Regarding sweet harmony Nuke, in your "estimation", how much clinical validation should move a theoretical conversation forward? - and any guesstimate - lousy or otherwise - on how much down time we are looking at to move this theory?

Sweet post,
Couch

[sulaco]

Nuke, recall that all PPHM's ISTs are open-label


for the Phase I, I/b, and II trials in Breast (Her-2 negative with Paclitaxel), Stage IV NSCLC (with carboplatin and permetrexed),and Liver HCC (with sorafenib), respectively. Enrollment for those trials is already complete. PPHM has data and is already studying clinical responses.

It's up to them whether they want to share this trial data with negotiators at the table. These are HUMAN trials with HUMAN results, which I agree, are paramount.

Always remember GILD what did with Pharmhasset's phase II data. GILD saw what it wanted, and struck quickly and without hesitation. For $12 billion. For one drug. For one indication.

Regards,

Joe